VivoSim Labs (VIVS) Total Liabilities (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Total Liabilities of $8.5 million for Q1 2026, up 104.06% year-over-year from $4.2 million in Q1 2025, and up 236.84% quarter-over-quarter from $2.5 million in Q4 2025.
VivoSim Labs (VIVS) Total Liabilities (2011 - 2026) Analysis & Trends
VivoSim Labs' Total Liabilities history runs 16 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 104.06% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 104.06% YoY), while the FY2026 annual figure was $8.5 million, up 104.06% from the prior year.
- Total Liabilities for Q1 2026 stood at $8.5 million, up from $2.5 million in the prior quarter.
- The five-year high for Total Liabilities was $8.5 million in Q1 2026, with the low at $2.4 million in Q2 2025.
- The 5-year median for Total Liabilities is $2.9 million (2022), against an average of $3.4 million.
- Peak annual rise in Total Liabilities reached 328.16% in 2022, while the deepest fall reached 92.45% in 2022.
- VivoSim Labs' Total Liabilities stood at $2.8 million in 2022, then retreated by 3.26% to $2.7 million in 2023, then rose by 28.94% to $3.5 million in 2024, then retreated by 27.61% to $2.5 million in 2025, then jumped by 236.84% to $8.5 million in 2026.
- Business Quant data shows VIVS's Total Liabilities at $8.5 million in Q1 2026, $2.5 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 6.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.19 Mn |
| Mar 31, 2026 | 8.49 Mn |
| Dec 31, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.62 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 4.16 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.98 Mn |
| Mar 31, 2023 | 4.98 Mn |
| Dec 31, 2022 | 2.79 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 2.89 Mn |
| Mar 31, 2022 | 3.09 Mn |
| Dec 31, 2021 | 3.80 Mn |
| Sep 30, 2021 | 35.88 Mn |